MyFinsight
Home
Blog
About
Proceeds from sale of
common stock
$200,000
(132.56%↑ Y/Y)
Net cash provided by
financing activities
$163,723
(-49.01%↓ Y/Y)
Canceled cashflow
$36,277
Expenses allocated by
sanovas on behalf of...
$165,375
(-50.00%↓ Y/Y)
Stock-based compensation
expense
$24,782
(-94.86%↓ Y/Y)
Increase in accrued
interest
$960
(-50.00%↓ Y/Y)
Amortization of rou asset
$642
Net (decrease) in
cash
$27,052
(618.14%↑ Y/Y)
Canceled cashflow
$136,671
Advances from related
parties, net
-$36,277
(-142.64%↓ Y/Y)
Total adjustments
$170,726
(-81.25%↓ Y/Y)
Canceled cashflow
$21,033
Net cash (used in)
operating activities
-$136,671
(58.11%↑ Y/Y)
Canceled cashflow
$170,726
Increase in accounts
payable and accrued...
-$20,559
(-121.73%↓ Y/Y)
Decrease in lease
liability
-$474
(-36.21%↓ Y/Y)
Net loss
-$307,397
(75.14%↑ Y/Y)
Back
Back
Cash Flow
RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. (RTGN)
source: myfinsight.com